Director William Waddill Exercises Options and Sells Shares in Protagonist Therapeutics

On June 23, 2026, William D. Waddill, a director of Protagonist Therapeutics, Inc. (PTGX), executed a series of transactions involving company stock. He exercised 9,000 stock options at $16.54 per share, acquiring 9,000 shares of common stock. Immediately following the exercise, he sold the same 9,000 shares at a weighted average price of $117.94 per share, with individual sale prices ranging from $117.00 to $119.07. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026. Following these transactions, Waddill's direct holdings decreased from 16,825 shares to 7,825 shares. The stock options exercised were fully vested and had an expiration date of May 27, 2030.